Table 1 Patient demographics and disease characteristics
Number (%) or mean (SD) or median (IQR: 25th–75th) | |
|---|---|
Country, n (%) | |
Australia | 217 (15%) |
China | 222 (16%) |
Indonesia | 98 (7%) |
Philippines | 124 (9%) |
Singapore | 219 (15%) |
Taiwan | 294 (21%) |
Thailand | 250 (18%) |
Ethnicity, n (%) | |
Caucasian | 116 (8%) |
Chinese | 699 (49%) |
Filipino | 132 (9%) |
Indonesian | 101 (7%) |
Thai | 254 (18%) |
Malay | 37 (3%) |
Vietnamese/Cambodian | 22 (2%) |
Indian/Sri Lankan | 35 (2%) |
Othera | 28 (2%) |
Gender, n (%) | |
Female | 1329 (93%) |
Highest attained education levelb | |
Primary | 241 (17%) |
Secondary | 548 (38%) |
Tertiary | 607 (42%) |
Age at diagnosis (years) | 31.1 (12.2) |
Disease duration (years) | 9.2 (7.7) |
SLICC-DI score | 0 (0–1) |
Damage presentc | 498 (35%) |
PGA at enrollment | 0.5 (0.2–1) |
Mild flare | 170 (12%) |
Severe flare | 100 (7%) |
SLEDAI-2 K | 4 (2–6) |
Current CNS activityd | 9 (0.6%) |
Current vasculitisd | 23 (1.6%) |
Current renal activityd | 369 (25.9%) |
Current musculoskeletal activityd | 119 (8.4%) |
Current cutaneous activityd | 273 (19.2%) |
Current serositisd | 12 (0.8%) |
Lupus low disease activity state (LLDAS) | 593 (42%) |
Number (%) of patients taking prednisoloneg | 1167 (82%) |
Taking immunosuppressante | 762 (53.5%) |
Taking antimalarialf | 1044 (73.3%) |